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Background and the purpose of the study: The cervico-vaginal mucosa which is populated with microflora
(mostly includes lactobacilli) is the portal of entry for sexually transmitted pathogens.
Methods: The in vitro anti-viral effect of vaginal and non-vaginal lactobacillus was evaluated using single cycle
HIV-1 replication and HSV-2 plaque reduction assays. The XTT proliferation assay was used to monitor the cellular
toxicity. The in vivo anti-HSV-1 activity was evaluated in BALB/c mouse model by monitoring skin lesion and
immune response development.
Results and major conclusion: DMEM culture supernatant of L. Gasseri and L. fermentum (PH 7.3) did not show
toxic effect but inhibited 50% of HIV replication at 12 and 31% concentrations, respectively. Co-culture of L. gasseri
(1000 CFU/ target cell) showed mild cytotoxicity but inhibited 68% of HIV replication. The supernatant of L. crispatus
inhibited 50% of HSV replication at 4% and also co-culture of L. gasseri, L. rhamnosus and L. crispatus revokes almost
all of the HSV multiplication. Culture supernatants of L. gasseri and L. crispatus had significant virucidal effect against
the HIV and HSV and inhibited HSV infection in a stage before viral entry to the target cells. Alive L. gasseri cells
showed high potential for inhibiting HSV-1 infection in vivo condition. Current data indicates that lactobacilli
supernatant encompasses components with neutralizing activity against HIV and HSV and it would be a
determinant factor for viral diseases transmission and promising lead for anti-viral probiotic design.
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The cervico-vaginal mucosa is the portal of entry for
sexually transmitted pathogenic microorganisms. In
child-bearing age healthy females, the vaginal protective
mucosa is populated with microflora that mostly
includes lactobacilli. Vaginal health is positively asso-
ciated with dominance of lactobacilli over pathogenic
anaerobes [1]. Bacterial vaginosis (BV) is a situation with
an imbalance of the vaginal microbial flora and is not
caused by specific pathogenic microorganisms [2]. Re-
duction, absence or lack of antimicrobial properties
(production of acid and H2O2) of lactobacilli and their
replacement by anaerobic microbes such as Gardnerella
vaginalis may be seen in BV [3].* Correspondence: modaresi@sina.tums.ac.ir
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distribution, and reproduction in any mediumIncreasing data indicate that lacking lactobacilli or ab-
normal vaginal flora facilitates the transmission of viral
sexually transmitted diseases (STD) [4]. There are some
data reporting that HIV seropositivity correlates with BV
independent of other behavior variabilities [5,6]. Recent
prospective investigations demonstrated the association
between vaginal flora alterations and the acquisition of
Human immunodeficiency virus (HIV) infection [7].
Also, reduction in vaginal flora lactobacillus content was
identified as a predisposing factor for infection of human
papillomavirus (HPV) and herpes simplex virus type
(HSV) [8-10]. Recent studies have revealed that abnor-
mal vaginal flora triggers the shedding of HSV and cyto-
megalovirus (CMV) in women genital tract [11,12]. On
the other hand genital herpes infection is a major risk
factor for acquisition and transmission of HIV via sexual
contact [13,14]. Moreover, HIV copy number in female
genital-tract discharge inversely correlates with lactoba-
cilli counts in bacterial flora [15].tral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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viral infections in both the female health protection as
well as reducing the risk of infection transmission to a
healthy man. In vitro studies have disclosed that hydro-
gen peroxide production by L. acidophilus strain displays
a virucidal effect against HIV-1 [16]. Additionally, it has
been reported that pre-incubation with different lactoba-
cillus strains reduces the infection titer of vesicular sto-
matitis virus (VSV) [17]. However the inhibition
mechanism of lactobacilli against viral infections is
poorly understood, but nevertheless metabolic products
such as lactic acid, H2O2 and bacteriocins are possible
mediators to account for the protection against viruses.
These factors might act against viral particles by inacti-
vation, epithelial cell attachment competition, mucin gel
preservation or maintaining the appropriate innate im-
mune response [18-20].
In spite of the clinical and epidemiological studies, the
in vitro anti-viral activity of these probiotic bacteria in cell
culture environment has not been investigated in detail.
The purpose of this study is to evaluate anti-HIV and
HSV activity of vaginal lactobacilli in vitro and in vivo
conditions and determine the possible mode of action.
Materials and methods
Lactobacilli strains and growth condition
Vaginal lactobacilli strains; L. crispatus ATCC33820, L.
gasseri ATCC33323, L. rhamnosus GG and L. fermentum
ATCC14931 were used in this study as well as the non-
vaginal ones; L. acidophilus LA-5 (Hansen company,
USA), L. paracasei subsp. Casei ATCC25302, L. acidoph-
ilus NCFM and L. casei CRL431 (Hansen company, USA).
All bacteria were stored at −70°C in 85% de Man- Rogosa-
Sharpe (MRS) supplemented with 15% glycerol. Lactoba-
cilli were inoculated from frozen glycerol vials onto MRS
broth and incubated at 37°C for 48hs under anaerobic
conditions [21]. Plating of serial lactobacilli 10-fold dilu-
tions in MRS-agar was used to determine the colony
forming units (CFU) titer. Colony counting was carried
out after 48hs of incubation.
Culture supernatant
Lactobacilli were harvested from fresh MRS culture by
centrifuging at 3 × 103 g and the pellet was washed with
DMEM twice to eliminate the remnants MRS. Working
stokes were prepared in DMEM (2 × 109 CFU/ml) and
stored at 4°C. These working stokes were freshly (no
more than 2 weeks) used for experiments. To prepare
the culture supernatant (CS), lactobacilli (3.6 × 108 CFU)
were inoculated onto each well of 6-wells plates contain-
ing 6 ml of high glucose DMEM and incubated for 20hs
in a CO2 incubator. Culture supernatant (neutral pH
phase) was harvested by clarification of the medium with
0.22 μm filters and used freshly for each experiment.Cell culture and transfection
HEK293T (Human emberionic kidney), Hela (Cervix
cancer) and vero (African green monkey kidney) cell
lines were cultured in Dulbecco’s Modified Eagle
Medium (DMEM, Gibco, USA) supplemented with 10%
fetal bovine serum (FBS, Gibco, USA), 5 mM glutamine.
The cells medium was supplemented with penicillin
(100 IU/ml) and streptomycin (100 μg/ml) in particular
experiments. HEK293T cells were transfected using
polyfect transfection reagent (Qiagen, USA). Transfec-
tion was performed according to the manufacturer’s
protocol in 6-wells plates [22].
Viruses
Single cycle replicable (SCR) HIV-1 (NL4-3) and HSV-2
viruses were used in this study. Plasmid mixture (2 μg)
of PmzNL4-3 [23], pSPAX.2 and pMD2G was cotrans-
fected into the HEK293T cells to prepare VSV surface
glycoprotein (VSVG) pseudotyped SCR HIV-1 [24].
Virus containing supernatant was harvested and pooled
24, 48 and 72hs post transfection.
Vero cells were infected to supply the HSV-2 virus
stokes. The Cells were seeded onto 6-wells plates (4.5 × 105
cells/well) and incubated for one day to reach 98% of con-
fluence. One milliliter of virus supernatant was used to in-
fect cells in each well and unbound virions were removed
after 2hs. Virus containing supernatants were harvested
and pooled every 24hs after infection until day 4.
HIV and HSV virus containing supernatants were clari-
fied using 0.22 μm filters and 10mins centrifuging at
104 g. Viruses were stored at −70°C and assessed for infec-
tious titer using replication and plaque reduction assays.
HIV replication assay
Single cycle replication assay was used to evaluate the
inhibitory activity against replication of VSVG psudo-
typed SCR HIV-1 virions [24,25]. Hela cells were seeded
in 96-wells plates (6 × 103 cells/well) and maintained for
24hs in antibiotic free medium. Lactobacilli cells or
supernatant were added into the wells 2hs before infec-
tion. Cells were infected with SCR HIV-1 virions (600 ng
P24) and incubated for 20hs to accelerate the virions ad-
sorption [22]. After virus entry, the cells were washed
two times with DMEM to remove unbound viral parti-
cles. Cells were fed with antibiotic containing medium
and incubated for additional 48 hrs. Plates were centri-
fuged for 15mins at 3 × 103 g and P24 content of the
cells supernatant was evaluated using P24 capture ELISA
(Biomerieux, France).
HSV plaque reduction assay
The inhibitory effect of lactobacilli against multiplication
of HSV was investigated using plaque reduction assay.
Vero cells were placed into the 24-wells culture plates
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incubated for 24hs (in antibiotic free medium) to reach
at least 98% of confluence. The cell monolayer was
infected with 50pfu of HSV and washed after 1hs to re-
move unbound virions. The cell monolayer were then
overlaid with DMEM supplemented by 1.5% of methyl-
cellulose, 5% FBS and antibiotics. After 72hs, the overlay
medium was removed and the cells were washed twice
with DMEM and fixed by methanol. The formed plaques
were counted after staining with 0.5% crystal violet.
Time-of-addition study
The inhibitory effect of L. gasseri and L. crispatus super-
natant against different intervals of HSV replication was
examined according to the previously described proced-
ure with some minor modifications [26]. Vero cells
monolayer was prepared by seeding the cells into 24-
well plates (Nunc, Denmark) as describe above. Then,
20% concentration of L. gasseri and L. crispatus CS were
added into the cells environment before (−6 and −2 hs),
during (0 hs) or after (2 and 6 hs) time course of HSV-2
infection. Afterwards, the procedures similar to plaque
reduction assay section were performed except that cell
monolayer was washed twice by DMEM to eliminate the
lactobacilli supernatant in pre-infection (−6, −2 and 0hs)
groups. In other groups the lactobacilli CS was added
after infection (2 and 6hs) and the concentration was
kept constant until the end of the test.
Virucidal assay
The direct effect of L. gasseri and L. crispatus CS on
HSV and HIV infectivity was evaluated by using viruci-
dal assay. Different concentrations (2, 20 and 50%) of
CSs were mixed thoroughly with HSV (5 × 103 pfu) and
HIV (1.2 × 103 P24) virions, in final volume of 10 μl. The
mixtures were incubated at 37°C for 2hs and then the
fresh medium (90 μl) was added to each tube. Residual
virus infectivity was determined by plaque reduction and
HIV replication assays as described above.
In vivo anti-HSV assay
Animal consisted of pathogen-free, female BALB/c mice
with 6–8 weeks of age-average 20 g of weight (purchased
from Pasteur Institute of Iran, Iran) were handled
according to the guidelines of the national institute of
health guide and care for use of laboratory animal, Iran.
The skin of BALB/c mice was shaved in right flank and
scratched by needle (gauge 22). The naked and scratched
skin was infected with 104 pfu of HSV-1 virions. Alive
lactobacilli suspension (105 CFU in 20 μl of PBS) was
added immediately after infection. Mice were maintained
for six weeks and then evaluated for skin lesions and
weight loss. The acyclovir cream (5%) was used as posi-
tive control. The immune response against HSV was alsomonitored by extracting the spleen cells and investigat-
ing their proliferative response to HSV antigens. Total
spleen cells were treated with lysis buffer to remove red
blood cells. Cell suspension was adjusted to 5.1 × 106
cells per milliliter and cultured (120 μl) in each well
of 96-well plates with 103pfu of inactivated HSV for
72hs. Phytohemagglutinin-A (PHA 7 μg/ml; Gibco,
USA) was used as control. The proliferation of the
cells was measured by addition of 50 μl of XTT
(sodium 3_-[1-(phenylaminocarbonyl)- 3,4-tetrazolium]-
bis(4-methoxy-6-nitro)benzene sulfonic acid; Roche,
Germany) into each well. The plates were incubated at
37°C for 2hs and then read at test and references wave-
lengths of 450 and 630 nm, respectively.
Cytotxicity assay
The toxicity of lactobacilli cells and supernatant for Vero
and Hela cells was determined using XTT (Roche,
Germany) proliferation assay as previously is described.
Vero cells were cultured in 96-wells plates (6 × 103/well)
(Nunc, Denmark) contain lactobacilli cells (6 × 107 CFU/
ml) and CS. Bacterial cells were removed after 1 hr and
antibiotic containing medium was added into the wells.
After 72hs, the medium was discarded and the cells were
subsequently rinsed with phosphate buffered saline
(PBS). To study the effect of lactobacilli cells and super-
natant on Hela cells viability, HIV replication assay
plates were subjected to the proliferation assay directly
after washing cells with PBS. The XTT reagent (40 μl/
well) was added into the plates and incubated at 37°C
for additional 3hs. The optical densities (OD) were mea-
sured using enzyme immunoassay reader (stat fax2100,
Awareness, USA) at test and reference wavelengths of
450 nm and 630 nm respectively.
Results and discussion
Anti-viral activity of lactobacilli supernatant
The DMEM culture supernatant (CS) of lactobacilli
(pH of 7.3) was used to appraise the overall anti-HIV
and HSV activity (Table 1). Virus multiplication was
significantly decreased by all lactobacilli CS, although
to different extents. L. gasseri, L. fermentum, L. acid-
ophilus and L. crispatus inhibited 50% of HIV-1 virions
replication at 12, 31, 46 and 48% concentration, re-
spectively. Parallel experiments were performed to in-
vestigate the anti-HSV-2 activity of lactobacilli CS
using plaque reduction assay. Lactobacilli CSs showed
very high activity for inhibition of HSV virions replica-
tion. L. crispatus CS inhibited plaques formation by
50% in the very low concentration (4%) that reveals
noteworthy anti-HSV activity of this strain. Other
lactobacilli also showed moderate to strong anti-HSV
activity. L. gasseri, L. acidophilus, L. rhamnosus and L.
casei inhibited the HSV replication with IC50 value of 11,
Table 1 The antiviral activity of lactobacilli supernatant
Lactobacilli strain Antiviral activity (%)
HIV-1 Inhibitory HSV-2 Inhibitory
IC50 (v/v) CC50 (v/v) IC50 (v/v) CC50 (v/v)
L. crispatus 48.5 ± 4.4 NT 4.2 ± 1.7 NT
L. acidophilus (Hansen co.) 46.3 ± 8.3 NT >50 NT
L. paracasei subsp. Casei ≥50 NT 43.1 ± 3.6 NT
L. rhamnosus ≥50 NT 17.7 ± 6.3 NT
L. fermentum 31.7 ± 4.1 ≥50 >50 ≥50
L. casei (Hansen co.) ≥50 NT 19.3 ± 1.6 NT
L. gasseri 12.2 ± 3.5 47.4 ± 2.1 11.2 ± 3.3 ≥50
L. acidophilus ≥50 NT 14.9 ± 5.2 NT
IC50 is a concentration (v/v) which is able to inhibit 50% of virus multiplication; CC50 is a concentration (v/v) which is 50% toxic for target cells; NT, Not toxic.
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activity for HSV but was not effective for inhibition of
HIV replication. This finding emphasizes the anti-HSV ac-
tive components of this strain inhibit HSV in a specific
manner.
The cytotoxicity results showed that the CS from vagi-
nal and non-vaginal lactobacilli had no toxicity for target
cells. This indicates the safety of these strains and select-
ive activity of their CS for reducing of viral replication
rather than cellular proliferation.
Moderate anti-HIV and strong anti-HSV activity of the
lactobacilli supernatants demonstrate that the lactoba-
cilli CS encompass molecules with considerable specific
activity for inhibition of viral replication. These data also
revealed notably difference between the anti-viral activity
of vaginal and non-vaginal strains (Table 1). The anti-
viral activity of lactobacilli due to disinfectant activity of
MRS culture supernatants was previously reportedFigure 1 The anti-viral potential of lactobacilli co-culture against HSV
cells environment one hour before infection and removed by washing afte
medium after infection.[16,27]. Although in this study the neutral pH lactoba-
cilli supernatant of lactobacilli in DMEM showed no
cytotoxicity but significant anti-viral activity implying
the presence of active compounds rather than disinfect-
ant activity.
The anti-viral activity of co-cultured lactobacilli
The potential of lactobacilli for inhibition of HSV-2 and
HIV-1 replication was studied by co-culturing the lacto-
bacilli with cells. Lactobacilli were added into the cells
environment considering physiological concentration in
vaginal environment (100 CFU/cell) one hour before in-
fection and removed by washing after viral adhesion to
the cells. Antibiotics were added to the medium after in-
fection to eradicate any growth of bacteria after viral
entry. The cytotoxicity of lactobacilli was investigated in
a parallel experiment. The vaginal lactobacilli strains (L.
gasseri, L. crispatus and L. rhamnosus) showed higher-2 and HIV infection in co-cultures. Lactobacilli were added to the
r viral adhesion to the cells. Cells were fed with antibiotic containing
Table 2 The virucidal effect of lactobacilli supernatant
Lactobacillus Strain HIV virucidal effect (%) HSV-2 virucidal effect (%)
2%v/v 20%v/v 50%v/v 2%v/v 20%v/v 50%v/v
L. crispatus 1.1 ± 0.5 8.5 ± 0.6 14.3 ± 3.3 15.6 ± 8.7 28.6 ± 3.9 76.4 ± 7.2
L. gasseri 4.3 ± 1.7 7.3 ± 1.5 15.4 ± 1.4 0.7 ± 0.2 6.3 ± 1.7 24.7 ± 3.2
L. rhamnosus 0.1 ± 0.02 2.1 ± 0.09 11.8 ± 0.01 4.2 ± 0.9 15.6 ± 2.1 38.3 ± 4.5
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seri blocked almost all of HSV virions infection however
L. crispatus and L. rhamnosus inhibited this virus by 93
and 84 percent, respectively. Approximately 68 and 31%
of HIV inhibition was observed by L. gasseri and L. fer-
mentum co-culture, whereas little inhibition was shown
by other lactobacilli strains investigated in this study.
Our results demonstrated that presence of vaginal lacto-
bacilli significantly reduces viral entry to the target cells
although the non-vaginal ones were apparently lesser
potent. All of investigated vaginal strains were active for
blocking HSV however only two strains (L. gasseri and
L. fermentum) had anti-HIV activity.Mode of anti-viral activity
Acording to the virucidal assay L. crispatus and L. gas-
seri inactivated 74 and 24%of HSV virions in 50% con-
centration, respectively (Table 2). The remarkable
virucidal activity of lactobacilli CS is in consistent with
the protective effect of lactobacilli against HSV and HIV
virion in co-culture condition (Figure 1), suggesting that
lactobacilli may secrete bacteriocins or other sort of
molecules with viral neutralization activity. This mode of
anti-viral activity is rather different from previously
reported ones (due to H2O2 and H
+ secretion) [27] sinceFigure 2 The inhibitory effect of L. gasseri and L. crispatus culture sup
supernatants (20%v/v) were added at different periods (before, during, and
eliminate lactobacilli supernatants prior to the inoculation of virions for preCS used in this study was in neutral pH and had no
toxic effect for target cells.
The culture supernatants of L. gasseri and L. crispatus
(20%) were added at different intervals (before, during,
and after) of HSV infection. The results showed that L.
gasseri and L. crispatus CS restrain HSV infection when
added −6 and -2hs before virion inoculation by 75 and
83%, respectively (Figure 2). However, the inhibitory rate
declined to 40 and 65% or less when L. gasseri and L.
crispatus CSs and virions were simultaneously added.
This data indicated that the lactobacilli supernatants
affect the initial stage of HSV-2 infection. The lactoba-
cilli products may inhibit HSV through disturbing the
adhesion of virions to the cells or neutralizing the viral
particles. This is a fairly new proposed mode of anti-
viral activity for lactobacilli which is different from held
belief that lactobacilli inactivate viral particles by lower-
ing PH and disinfectant agent secretion [27].
The in vivo anti-HSV activity
The anti-HSV-1 activity of L. crispatus and L. gasseri,
strains with highest potential in vitro experiments, was
studied in BALB/c mice model. Alive L. gasseri cells
showed significant activity for protecting mice against
HSV-1 virions infection. As it can be seen in Figure 3, L.
gasseri treated mice raised normal hairs while comparativeernatants against different stages of HSV-2 infection. Culture
after) of HSV infection. The cells were washed twice by DMEM to
-infection (−6, −2 and 0 h) groups.
A. B.
C. D.
Figure 3 Skin lesions 6 weeks after cutaneous infection of
HSV-1 in BALB/c mice. The shaved and scratch skin of right flank
was infected with 104pfu of HSV-1 and the development of skin
lesions was monitored after 6 weeks. The hair loss in the site of
infection was clearly seen in infected mice (A) in comparison with
ones treated with acyclovir cream (5%) (B). L. gasseri treated mice
raised normal hairs (C) while comparative hair loss can be seen
in L. crispatus (D).
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The 6.5 and 8.8 g of weight loss was just observed in mice
which received L. crispatus or no treatment, respectively
(Table 3). To prove the inhibitory activity of L. gasseri
against HSV infection the lymphocyte cells were extracted
from mice spleen and evaluated for proliferation response
to HSV antigens. Spleen cells from Acyclovir and L. gasseri
treated mice showed no response to viral antigens with
stimulation index (SI) values of 1.01 and 1.05 (Table 3).
These data indicates that immune cells were not exposed
to HSV antigens which unequivocally show inhibition of
establishment of infection. The findings of this study lead
to the conclusion that L. gasseri cells have comparable po-
tential for inhibition of HSV infection in vivo condition to
Acyclovir.Conclusion
The results of the present study reveal the anti-HSV and
HIV effect of lactobacilli by production of anti-viral
molecules and other possible mechanisms. Infection was
significantly reduced with no cytotoxicity if HSV andTable 3 The in vivo anti-HSV activity of lactobacilli
Lactobacilli
strain









L. crispatus 6.5 ± 0.4 1.7 ± 0.6 1.684 ± 0.43 1.9 ± 0.2
L. gasseri 0 ± 0.1 0.07 ± 0.2 0.876 ± 0.12 1.05 ± 0.3
Negative
control
8.8 ± 0.3 4.1 ± 0.3 1.882 ± 0.62 2.1 ± 0.1
Acyclovir 0 ± 0.2 0.09 ± 0.01 0.793 ± 0.31 1.01 ± 0.2HIV were cultured in the presence of living lactobacilli
cells. The presence of lactobacilli cells was not necessary
for inhibitory activity since virus replication is also
inhibited in the presence of neutral pH supernatants. Va-
ginal lactobacilli strains were able to inhibit the first
stages of HSV infection. The anti-viral activity of lacto-
bacilli cells in the midst of herpes virus binding to the
target cell was strain-dependent. L. gasseri showed in-
hibitory activity against HIV virions among investigated
lactobacilli in this study. Numerous mechanisms may be
involved in the inhibitory effect of lactobacilli against
HSV and HIV such as: interfering with the early steps of
virus infection, viral particle neutralizing and secretion
of compounds with the ability of blocking the intracellu-
lar events of virus replication. The in vivo experiment
confirmed the anti-viral activity of lactobacilli in mouse
models. Potent lactobacilli could be promising probiotic
candidates for protection against HSV and HIV or other
viruses infections transmission.
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